We’re committed to helping improve sight for more than 40 million patients in the U.S. and around the world.
This week, we announced a more than $1 billion investment in Jacksonville, Florida to strengthen our Vision operations.
As part of our $55 billion U.S. investment in
#NEWS: The U.S. FDA has approved our new treatment for patients 12 and older with moderate to severe plaque psoriasis, bringing a fundamentally different systemic treatment option to patients and physicians.
Learn more: social.jnj.com/3NlAPK5
For U.S. Audience Only
#NEWS: The U.S. FDA has approved a breakthrough extended depth of focus (EDOF) intraocular lens intended for use in cataract surgery.
This advanced technology is designed to deliver clarity of vision with reduced visual symptoms, helping patients see the world as they expect¹.
#NEWS The U.S. FDA has approved a new subcutaneously administered therapy for the treatment of EGFR-mutated advanced non–small cell lung cancer (NSCLC) in adults.
This treatment option brings us one step closer to delivering more personalized care centered on the patient
Today, the U.S. FDA approved one of our therapies as an adjunctive treatment for adults living with major depressive disorder (MDD) – offering hope to the 2 in 3 patients who experience residual symptoms despite their antidepressant treatment. Learn more here:
What's the difference between AI hype and AI value in healthcare? At #HLTHUSA, our CIO Jim Swanson shared what successful teams focus on to deliver real results that advance health.
Driven by our commitment to closing the gap between communities and care, we're excited to announce that we're teaming up with the @nyjets to promote better health in the local community, which is home to both our world headquarters and the Jets.
Join us in honoring healthcare
We’re gearing up for #HLTHUSA October 19-22. Don’t miss sessions on AI’s real-world impact, breaking barriers in cancer care and how nurses are fueling healthcare innovation: social.jnj.com/48P34cz
Today we’re announcing our intent to separate our Orthopaedics business. We’re confident this move would further strengthen the focus of Johnson & Johnson on our six key growth areas – Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. It would also
Struggling to see clearly due to astigmatism and finding it hard to focus up close from presbyopia?
We're changing that with ACUVUE® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM—the first and only daily disposable contact lens designed to treat both astigmatism and presbyopia.¹
